These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 36498738

  • 1. Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD.
    Huang WC, Chen CY, Liao WC, Wu BR, Chen WC, Tu CY, Chen CH, Cheng WC.
    J Clin Med; 2022 Dec 01; 11(23):. PubMed ID: 36498738
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD.
    Weng CF, Wu CC, Wu MH, Lin FJ.
    Chest; 2023 Apr 01; 163(4):799-814. PubMed ID: 36442662
    [Abstract] [Full Text] [Related]

  • 3. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
    Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.
    Adv Ther; 2017 Nov 01; 34(11):2518-2533. PubMed ID: 29094315
    [Abstract] [Full Text] [Related]

  • 4. A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.
    Muraki M, Kunita Y, Shirahase K, Yamazaki R, Hanada S, Sawaguchi H, Tohda Y.
    BMC Pulm Med; 2021 Jan 13; 21(1):26. PubMed ID: 33441146
    [Abstract] [Full Text] [Related]

  • 5. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, Crossingham I, Evans DJ.
    Cochrane Database Syst Rev; 2019 Mar 06; 3(3):CD012930. PubMed ID: 30839102
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment.
    Cheng SL.
    J Clin Med; 2021 Jun 16; 10(12):. PubMed ID: 34208599
    [Abstract] [Full Text] [Related]

  • 7. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S, Palli SR, Bengtson LGS, Buysman EK, Clark B, Sargent A, Shaikh A, Ferguson GT.
    J Manag Care Spec Pharm; 2023 Jul 16; 29(7):791-806. PubMed ID: 37133429
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD.
    Banerji D, Mahler DA, Hanania NA.
    Expert Rev Respir Med; 2016 Jul 16; 10(7):767-80. PubMed ID: 27223863
    [Abstract] [Full Text] [Related]

  • 9. Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis.
    Alcázar Navarrete B, Boucot I, Naya I, Tombs L, Lipson DA, Compton C, Sousa AR, Feldman G.
    Pulm Ther; 2018 Dec 16; 4(2):171-183. PubMed ID: 32026389
    [Abstract] [Full Text] [Related]

  • 10. Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
    Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Dec 16; 18():1431-1444. PubMed ID: 37465818
    [Abstract] [Full Text] [Related]

  • 11.
    ; 2015 12 16. PubMed ID: 30883067
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study.
    Plate T, Friedrich FW, Beier J.
    Int J Chron Obstruct Pulmon Dis; 2020 12 16; 15():1335-1347. PubMed ID: 32606643
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
    Driessen MT, Whalen J, Seewoodharry Buguth B, Vallejo-Aparicio LA, Naya IP, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F, Risebrough NA.
    Respir Res; 2018 Nov 20; 19(1):224. PubMed ID: 30458866
    [Abstract] [Full Text] [Related]

  • 14. Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
    Hsieh MJ, Chen NH, Cheng SL, Tao CW, Wei YF, Wu YK, Chan MC, Liu SF, Hsu WH, Yang TM, Lin MS, Liu CL, Kuo PH, Tsai YH.
    Int J Chron Obstruct Pulmon Dis; 2022 Nov 20; 17():967-976. PubMed ID: 35510163
    [Abstract] [Full Text] [Related]

  • 15. Which LABA/LAMA should be chosen in COPD patients in real life?
    Sposato B, Petrucci E, Serafini A, Lena F, Lacerenza LG, Montagnani A, Alessandri M, Cresti A, Scala R, Rogliani P, Ricci A, Perrella A, Scalese M.
    Pulm Pharmacol Ther; 2021 Dec 20; 71():102076. PubMed ID: 34530132
    [Abstract] [Full Text] [Related]

  • 16. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study.
    Wang MT, Lai JH, Huang YL, Liou JT, Cheng SH, Lin CW, Pan HY, Hsu YJ, Tsai CL.
    Chest; 2021 Oct 20; 160(4):1255-1270. PubMed ID: 34023320
    [Abstract] [Full Text] [Related]

  • 17. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
    Calzetta L, Di Marco F, Blasi F, Cazzola M, Centanni S, Micheletto C, Rossi A, Rogliani P.
    Pulm Pharmacol Ther; 2019 Dec 20; 59():101855. PubMed ID: 31639476
    [Abstract] [Full Text] [Related]

  • 18. Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England.
    Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo C, Yeap J, Wild R, Compton C, Rothnie KJ, Herth FJF, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Dec 20; 18():2039-2054. PubMed ID: 37731774
    [Abstract] [Full Text] [Related]

  • 19. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT, Brown N, Compton C, Corbridge TC, Dorais K, Fogarty C, Harvey C, Kaisermann MC, Lipson DA, Martin N, Sciurba F, Stiegler M, Zhu CQ, Bernstein D.
    Respir Res; 2020 May 29; 21(1):131. PubMed ID: 32471423
    [Abstract] [Full Text] [Related]

  • 20. Real-world comparative effectiveness of three single-inhaler dual bronchodilators for the treatment of COPD.
    Li J, Dell'Aniello S, Ernst P, Suissa S.
    Eur Respir J; 2023 Aug 29; 62(2):. PubMed ID: 37343975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.